Biomarker Concentrations at Baseline and Short‐Term Changes
chronic kidney disease, nonobstructive coronary arteries, obstructive coronary artery disease, dyslipidemia, heart failure, diabetes
MYOCARDIAL INFARCTION, ISCHEMIC STROKE, PERIPHERAL VASCULAR DISEASE, DYSLIPIDEMIA, REGRESSION, HEART FAILURE, HYPERTENSION, DIABETES
Baseline concentrations of hs‐cTnT, NT‐proBNP, hs‐CRP, and GDF‐15 in the total cohort of patients with MINOCA and MI‐CAD are presented in Table Biomarker Concentrations and Multiple Linear Regression Results in the Total Cohort at BaselineInflammationOxidative stressHypoxiaBiomarker data presented as medians (with interquartile ranges). Model 1: unadjusted. Model 2: adjusted for baseline clinical characteristics (age, sex, body mass index, current smoking, hypertension, dyslipidemia [medical history and/or lipid treatment at admission], diabetes, chronic kidney disease [medical history], myocardial infarction [MI] type [ST‐segment–elevation MI/non–ST‐segment–elevation MI], previous MI, previous ischemic stroke, previous heart failure, peripheral vascular disease, and hours from the onset of symptoms to blood sampling). GDF‐15 indicates growth differentiation factor 15; hs‐CRP, high‐sensitivity C‐reactive protein; hs‐cTnT, high‐sensitivity cardiac troponin T; MI‐CAD, MI with obstructive coronary artery disease; MINOCA, MI with nonobstructive coronary arteries; and NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.Statistically significant values.Crude hs‐cTnT concentrations were similar between patients with MINOCA and MI‐CAD (Table Patients with MINOCA had higher crude NT‐proBNP concentrations compared with those with MI‐CAD (Table hs‐CRP concentrations were higher in patients with MINOCA compared with MI‐CAD in both crude and adjusted analyses (Table The crude GDF‐15 concentrations were similar between patients with MINOCA and MI‐CAD (Table 